iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer

Iteos Therapeutics developing novel cancer immunotherapies, announced the first cohort of patients has been dosed in its Phase 1/1b study with EOS100850, the Company’s investigational A2A receptor antagonist and lead program candidate. Discover the press release here.

Read more

Promethera Biosciences Announces Late-Breaking Data Presentation at EASL 2019 from World First Liver Stem Cell Clinical Trial in ACLF

Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem® in patients with Acute-on-Chronic Liver Failure (ACLF) or acute decompensation (AD) at risk of developing ACLF has been selected by the European Association for the Study of the Liver (EASL) for an oral presentation, by the principal investigator (Prof. F. Nevens, KULeuven, BE) during the plenary general session at The International Liver Congress™ (ILC) 2019 being held April 10-14, 2019, in Vienna, Austria. Discover the press release here.

Read more